ArticleFrontiers in veterinary science2025
Medium-term storage of platelet-derived orthobiologics: a feasible alternative for equine practice.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Platelet-rich plasma (PRP) is commonly used by equine veterinarians. Although PRP is considered a feasible and affordable orthobiologic, its use has been associated with certain drawbacks, such as the time required for protocols and the necessity of using a fresh product, which is usually prepared at the time of use. In this context, the present study aimed to produce PRP-derived orthobiologics with the potential to be stored for longer periods while maintaining similar growth factor contents. Methods: PRP was prepared from six donors and subjected to additional processing: lysis, yielding Platelet Lysate (PL), and freeze-drying, yielding lyophilized PRP (FD-PRP). The three products were stored for 30 days at different temperatures (-80°C, -20°C, and room temperature [RT]). Additionally, orthobiologics from a single donor were also subjected to longer periods of storage: PRP, FD-PRP, and PL for 1 and 2 years at -80°C and -20°C; and FD-PRP at RT was stored for 1 year with cryoprotectant and 30 days without cryoprotectant. Results: Storage for 30 days presented distinct pattern related to the temperatures on each orthobiologic: there was no difference on TGF-β1 concentrations between the hemocomponents at -80°C, PL retained a high TGF-β1 concentration at -20°C, PRP and FD-PRP showed a slight increase in TGF-β1 content at RT when compared to PL. RT also resulted in decreases in IL-1β, IL-10, and TNF-α concentrations in all hemocomponents. Discussion: The protocols used in this study efficiently produced hemocomponents with similar content, offering some benefits, such as the possibility of preparing major volumes at the same time, preparing aliquots that would be ready to be used throughout the entire treatment, and storing them in farms, clinics, and hospitals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.